DGAP-News

RedHill Biopharma Ltd.: RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT(TM) for Migraines with Grupo JUSTE in Spain and Additional Potential Territories

DGAP-News: RedHill Biopharma Ltd. / Key word(s): Contract
RedHill Biopharma Ltd.: RedHill Biopharma and IntelGenx Announce Definitive
Agreement for Commercialization of RIZAPORT(TM) for Migraines with Grupo
JUSTE in Spain and Additional Potential Territories

18.07.2016 / 13:30
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press Release

RedHill Biopharma and IntelGenx Announce Definitive Agreement for
Commercialization of RIZAPORT(TM) for Migraines with Grupo JUSTE in Spain
and Additional Potential Territories

- RedHill and its co-development partner, IntelGenx, have signed a
definitive agreement with Grupo JUSTE granting an exclusive license to
commercialize their acute migraine drug RIZAPORT(TM) in Spain, and a
right of first refusal for additional territories

- Grupo JUSTE is a prominent private Spanish company with over 90 years
of experience in the research, development and commercialization of
proprietary pharmaceutical products, including migraine and other
central nervous system (CNS) drugs in Europe, Latin America and other
territories


- RIZAPORT(TM) was recently approved for marketing in Germany under the
European Decentralized Procedure (DCP); RedHill and IntelGenx continue
to work together to secure additional commercialization partners for
RIZAPORT(TM) in the U.S., Europe and other territories

TEL-AVIV, Israel, July 18, 2016 RedHill Biopharma Ltd. (NASDAQ: RDHL)
(TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company
primarily focused on development and commercialization of late clinical-
stage, proprietary, orally-administered, small molecule drugs for
inflammatory and gastrointestinal diseases and cancer, together with
IntelGenx Corp. (TSXV: IGX; OTCQX: IGXT) ("IntelGenx"), a Canadian drug
delivery company focused on oral drug delivery, announced the signing
of an exclusive license agreement with Grupo JUSTE S.A.Q.F ("Grupo JUSTE"),
for the commercialization of RIZAPORT(TM) in Spain, and a right of first
refusal for additional territories. RIZAPORT(TM) is a proprietary oral thin
film formulation of rizatriptan for the treatment of acute migraines.

Grupo JUSTE is a prominent private Spanish company with over 90 years of
experience in the research, development and commercialization of
proprietary pharmaceutical products, including migraine and other central
nervous system (CNS) drugs, in Europe, Latin America and other territories.